Cargando…

Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19

Engineered natural killer (NK) cells represent a promising option for immune therapy option due to their immediate availability in allogeneic settings. Severe acute diseases, such as COVID-19, require targeted and immediate intervention. Here we show engineering of NK cells to express (1) soluble in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Ting, Ma, Rui, Dong, Wenjuan, Teng, Kun-Yu, Kollath, Daniel S., Li, Zhiyao, Yi, Jinhee, Bustillos, Christian, Ma, Shoubao, Tian, Lei, Mansour, Anthony G., Li, Zhenlong, Settles, Erik W., Zhang, Jianying, Keim, Paul S., Barker, Bridget M., Caligiuri, Michael A., Yu, Jianhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095674/ https://www.ncbi.nlm.nih.gov/pubmed/35546150 http://dx.doi.org/10.1038/s41467-022-30216-8

Ejemplares similares

Off-the-shelf CAR–engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia
por: Mansour, Anthony G., et al.
Publicado: (2023)

A four-stage model for murine natural killer cell development in vivo
por: Ma, Shoubao, et al.
Publicado: (2022)

PDGF-D−PDGFRβ signaling enhances IL-15–mediated human natural killer cell survival
por: Ma, Shoubao, et al.
Publicado: (2022)

Factor Xa cleaves SARS-CoV-2 spike protein to block viral entry and infection
por: Dong, Wenjuan, et al.
Publicado: (2023)

FXa cleaves the SARS-CoV-2 spike protein and blocks cell entry to protect against infection with inferior effects in B.1.1.7 variant
por: Dong, Wenjuan, et al.
Publicado: (2021)

ILC1s Control Leukemia Stem Cell Fate and Limit Development of AML
por: Li, Zhenlong, et al.
Publicado: (2022)

Human ILC1s target leukemia stem cells and control development of AML
por: Caligiuri, Michael, et al.
Publicado: (2023)

The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity
por: Ma, Shoubao, et al.
Publicado: (2021)

CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma
por: Chu, Jianhong, et al.
Publicado: (2013)

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
por: Yilmaz, Ahmet, et al.
Publicado: (2020)

The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus
por: Dong, Wenjuan, et al.
Publicado: (2022)

Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells
por: Juillerat, Alexandre, et al.
Publicado: (2020)

Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells
por: Alvarez-Breckenridge, Christopher A., et al.
Publicado: (2012)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
por: Cooper, Matthew L., et al.
Publicado: (2018)

An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
por: Xiang, Jingyu, et al.
Publicado: (2023)

The mysterious desert dwellers: Coccidioides immitis and Coccidioides posadasii, causative fungal agents of coccidioidomycosis
por: Kollath, Daniel R., et al.
Publicado: (2019)

PM10 and Other Climatic Variables Are Important Predictors of Seasonal Variability of Coccidioidomycosis in Arizona
por: Kollath, Daniel R., et al.
Publicado: (2022)

Are natural killer cells superior CAR drivers?
por: Klingemann, Hans
Publicado: (2014)

Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
por: Cutmore, Lauren C., et al.
Publicado: (2021)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Advantages and applications of CAR-expressing natural killer cells
por: Glienke, Wolfgang, et al.
Publicado: (2015)

Editorial: Natural Killer Cells in Tissue Compartments
por: Vitale, Massimo, et al.
Publicado: (2020)

The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy
por: Fabian, Kellsye P., et al.
Publicado: (2021)

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma
por: Simon, Bianca, et al.
Publicado: (2018)

Current Progress in CAR-T Cell Therapy for Solid Tumors
por: Ma, Shuo, et al.
Publicado: (2019)

Targeting the RNA m(6)A modification for cancer immunotherapy
por: Li, Xinxin, et al.
Publicado: (2022)

Dependence of innate lymphoid cell 1 development on NKp46
por: Wang, Yufeng, et al.
Publicado: (2018)

An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma
por: Xu, Bo, et al.
Publicado: (2021)

Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention
por: Li, Yan-Ruide, et al.
Publicado: (2022)

Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2020)

CAR‐NK cells from engineered pluripotent stem cells: Off‐the‐shelf therapeutics for all patients
por: Lu, Shi‐Jiang, et al.
Publicado: (2021)

P522: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL
por: Huang, Ruihao, et al.
Publicado: (2023)

Enhancing Effects of Environmental Enrichment on the Functions of Natural Killer Cells in Mice
por: Xiao, Run, et al.
Publicado: (2021)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL
por: Ureña-Bailén, Guillermo, et al.
Publicado: (2022)

Natural killer cells for cancer immunotherapy: a new CAR is catching up
Publicado: (2019)

How can Cytokine-induced killer cells overcome CAR-T cell limits
por: Cappuzzello, Elisa, et al.
Publicado: (2023)

Targeting FLT3 by Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
por: Chen, Lichao, et al.
Publicado: (2017)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i75k3qfvvkguo4ltnhvs0t57cc